BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 34335481)

  • 1. Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.
    Fullmer T; Cabanillas ME; Zafereo M
    Front Endocrinol (Lausanne); 2021; 12():720723. PubMed ID: 34335481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer.
    Kirtane K; Roth MY
    Curr Treat Options Oncol; 2020 Feb; 21(3):18. PubMed ID: 32048061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinase inhibitors in thyroid cancers.
    Sukrithan V; Jain P; Shah MH; Konda B
    Endocr Oncol; 2023 Jan; 3(1):e220062. PubMed ID: 37434642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer.
    Ibrahim EY; Busaidy NL
    Curr Opin Oncol; 2017 Mar; 29(2):151-158. PubMed ID: 28141684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Horizons: Emerging Therapies and Targets in Thyroid Cancer.
    Ringel MD
    J Clin Endocrinol Metab; 2021 Jan; 106(1):e382-e388. PubMed ID: 32977343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.
    Dadu R; Cabanillas ME
    Minerva Endocrinol; 2012 Dec; 37(4):335-56. PubMed ID: 23235190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard and emerging therapies for metastatic differentiated thyroid cancer.
    O'Neill CJ; Oucharek J; Learoyd D; Sidhu SB
    Oncologist; 2010; 15(2):146-56. PubMed ID: 20142332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.
    Narayanan S; Colevas AD
    Curr Treat Options Oncol; 2016 Jun; 17(6):30. PubMed ID: 27139457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
    Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
    Liu J; Liu Y; Lin Y; Liang J
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
    Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
    Gosain R; Alexander JS; Gill A; Perez C
    Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
    Kojic KL; Kojic SL; Wiseman SM
    Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Aggressive Thyroid Cancer.
    Huang J; Harris EJ; Lorch JH
    Surg Pathol Clin; 2019 Dec; 12(4):943-950. PubMed ID: 31672300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions.
    Porter A; Wong DJ
    Front Oncol; 2020; 10():592202. PubMed ID: 33569345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer.
    Boucher A; Ezzat S; Hotte S; Rachinsky I; Rajaraman M; Ruether D; Wiseman SM; Brierley J; Ho C; Krzyzanowska M; Lamond N; Massicotte MH; Joseph S; Herscovitch K; Sikora L; Winquist E
    Oral Oncol; 2021 Oct; 121():105477. PubMed ID: 34388408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
    Ricarte-Filho JC; Ryder M; Chitale DA; Rivera M; Heguy A; Ladanyi M; Janakiraman M; Solit D; Knauf JA; Tuttle RM; Ghossein RA; Fagin JA
    Cancer Res; 2009 Jun; 69(11):4885-93. PubMed ID: 19487299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid Cancer: A Review.
    Boucai L; Zafereo M; Cabanillas ME
    JAMA; 2024 Feb; 331(5):425-435. PubMed ID: 38319329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance.
    Hamidi S; Hofmann MC; Iyer PC; Cabanillas ME; Hu MI; Busaidy NL; Dadu R
    Front Endocrinol (Lausanne); 2023; 14():1176731. PubMed ID: 37435488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Treatment of Well-Differentiated Thyroid Carcinoma.
    Paschke R; Lincke T; Müller SP; Kreissl MC; Dralle H; Fassnacht M
    Dtsch Arztebl Int; 2015 Jun; 112(26):452-8. PubMed ID: 26205749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.